Terms: = Prostate cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM
272 results:
1. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic prostate cancer Can Identify New Actionable Alterations.
Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).
Sasaki T; Ebara S; Tatenuma T; Ikehata Y; Nakayama A; Kawase M; Toide M; Yoneda T; Sakaguchi K; Teishima J; Makiyama K; Kitamura H; Saito K; Koie T; Koga F; Urakami S; Inoue T
World J Urol; 2024 Mar; 42(1):152. PubMed ID: 38483586
[TBL] [Abstract] [Full Text] [Related]
3. Non-medical interventions to enhance return to work for people with cancer.
de Boer AG; Tamminga SJ; Boschman JS; Hoving JL
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD007569. PubMed ID: 38441440
[TBL] [Abstract] [Full Text] [Related]
4. Hyperthyroidism and the risk of non-thyroid cancer: a Danish register-based long-term follow-up study.
Riis T; Bonnema SJ; Brix TH; Folkestad L
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38367342
[TBL] [Abstract] [Full Text] [Related]
5. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
6. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
7. Associations between BMI in youth and site-specific cancer in men-A cohort study with register linkage.
Onerup A; Mehlig K; Af Geijerstam A; Ekblom-Bak E; Kuhn HG; Lissner L; Rosengren A; Börjesson M; Åberg M
Obesity (Silver Spring); 2024 Feb; 32(2):376-389. PubMed ID: 37927128
[TBL] [Abstract] [Full Text] [Related]
8. [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].
Yuan CW; Li R; Li ZH; Liu Y; Shan GZ; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):838-842. PubMed ID: 37807737
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of Health-Related Quality of Life Changes in prostate cancer Patients Undergoing Laparoscopic versus Robotic-Assisted Laparoscopic Radical prostatectomy: A Systematic review.
Yazici S; Tonyali S
Urol J; 2024 Feb; 21(1):14-19. PubMed ID: 37727913
[TBL] [Abstract] [Full Text] [Related]
10. A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients.
Hu B; Zhang H; Zhang Y; Jin Y
Cancer Imaging; 2023 Sep; 23(1):82. PubMed ID: 37667393
[TBL] [Abstract] [Full Text] [Related]
11. Associations of intakes of total protein, protein from dairy sources, and dietary calcium with risks of colorectal, breast, and prostate cancer: a prospective analysis in UK Biobank.
Watling CZ; Kelly RK; Dunneram Y; Knuppel A; Piernas C; Schmidt JA; Travis RC; Key TJ; Perez-Cornago A
Br J Cancer; 2023 Sep; 129(4):636-647. PubMed ID: 37407836
[TBL] [Abstract] [Full Text] [Related]
12. The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: Results of a stepped-wedge cluster randomised trial.
Politi MC; Forcino RC; Parrish K; Durand MA; O'Malley AJ; Moses R; Cooksey K; Elwyn G
Health Expect; 2023 Oct; 26(5):2023-2039. PubMed ID: 37394739
[TBL] [Abstract] [Full Text] [Related]
13. Combination of metabolomics and network pharmacology analysis to decipher the mechanisms of total flavonoids of Litchi seed against prostate cancer.
Cui D; Luo Z; Liu X; Chen X; Zhang Q; Yang X; Lu Q; Su Z; Guo H
J Pharm Pharmacol; 2023 Jul; 75(7):951-968. PubMed ID: 37167442
[TBL] [Abstract] [Full Text] [Related]
14. Salvage Radiation Therapy After Radical prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Petersen PM; Cook AD; Sydes MR; Clarke N; Cross W; Kynaston H; Logue J; Neville P; ; Payne H; Parmar MKB; Parulekar W; Persad R; Saad F; Stirling A; Parker CC; Catton C
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):624-629. PubMed ID: 37150260
[TBL] [Abstract] [Full Text] [Related]
15. A Contemporary Evaluation of Urological Outcomes After Renal Transplantation.
Kennedy A; Rice MK; Waguespack M; Xie WY; Al-Qaoud T; Malik RD
Urol Pract; 2023 Jan; 10(1):75-81. PubMed ID: 37103439
[TBL] [Abstract] [Full Text] [Related]
16. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Validation and Treatment Plan Evaluation Based on Autodelineation of the Clinical Target Volume for prostate cancer Radiotherapy.
Shen J; Tao Y; Guan H; Zhen H; He L; Dong T; Wang S; Chen Y; Chen Q; Liu Z; Zhang F
Technol Cancer Res Treat; 2023; 22():15330338231164883. PubMed ID: 36991566
[TBL] [Abstract] [Full Text] [Related]
19. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
Soyano T; Kozuka T; Kashihara K; Murakami Y; Yonese J; Sasamura K; Shimoyachi N; Kashihara T; Yoshioka Y; Oguchi M
Jpn J Clin Oncol; 2023 Jun; 53(6):514-521. PubMed ID: 36946312
[TBL] [Abstract] [Full Text] [Related]
20. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
[TBL] [Abstract] [Full Text] [Related]
[Next]
